Avastin (bevacizumab) is not a last resort. It is FDA-approved as a first-line treatment for several cancers, meaning oncologists regularly prescribe it as one of the initial therapies a patient receives. The perception that it’s only used when nothing else works likely stems from the fact that it’s also approved for recurrent or hard-to-treat cancers, but that’s only part of the picture.
Where Avastin Fits in Treatment Order
Avastin’s role depends entirely on which cancer is being treated. For some cancers, it’s among the first drugs your oncologist will reach for. For others, it enters the picture after earlier treatments have stopped working. Here’s how that breaks down across its FDA-approved uses:
- First-line uses: Avastin is approved as a first-line therapy for metastatic colorectal cancer, non-squamous non-small cell lung cancer, stage III or IV ovarian cancer (after surgery), and liver cancer that hasn’t been treated with other systemic drugs. In these cases, it’s given alongside chemotherapy right from the start.
- Second-line uses: For metastatic colorectal cancer that has progressed on an initial treatment plan, Avastin can also be used in the second round of therapy.
- Recurrent or advanced disease: For glioblastoma (a type of brain cancer), cervical cancer, and certain ovarian cancers that have come back after prior treatment, Avastin is approved for use at later stages. In recurrent glioblastoma specifically, it has become a standard treatment option after the cancer returns.
So calling Avastin a “last resort” flattens a much more nuanced reality. In lung cancer, for example, it’s paired with chemotherapy as part of the very first treatment a patient receives. In recurrent brain cancer, it’s used after the tumor comes back, but it’s still considered a standard approach rather than a desperation measure.
How Avastin Works Differently Than Chemotherapy
Part of the confusion may come from Avastin’s mechanism, which is fundamentally different from traditional chemotherapy. Chemotherapy drugs directly attack cancer cells. Avastin takes a different approach: it blocks a protein called VEGF that tumors rely on to grow new blood vessels. Without a blood supply, tumors can’t get the oxygen and nutrients they need to keep growing.
This concept, first proposed by researcher Judah Folkman in 1971, represented a shift in cancer treatment from killing cancer cells directly to cutting off their support system. Avastin was one of the first drugs to target the tumor’s environment rather than the tumor cells themselves, and it’s typically given alongside chemotherapy to attack the cancer on two fronts simultaneously.
What the Survival Data Shows
When Avastin is used as a first-line treatment, the outcomes reflect a drug working early in the disease course, not as a last-ditch effort. In metastatic colorectal cancer, patients treated with Avastin plus chemotherapy combinations had a median overall survival of roughly 23 to 26 months, depending on which chemotherapy regimen was used. Median progression-free survival (the time before the cancer started growing again) was about 10.8 months overall, with certain drug combinations pushing that closer to 11.6 months.
In non-squamous lung cancer, a major clinical trial established Avastin combined with carboplatin and paclitaxel as a standard of care for first-line treatment. These aren’t the outcomes of a drug reserved for patients who’ve run out of options.
Risks Worth Knowing About
Avastin does carry serious risks, which may contribute to why some people assume it’s only used when the situation is dire. Because it affects blood vessel formation throughout the body, it can cause side effects that standard chemotherapy doesn’t.
Gastrointestinal perforation (a hole forming in the stomach or intestinal wall) occurs in 0.3% to 3.2% of patients, and some cases are fatal. Wound healing complications are significantly more common in patients who undergo surgery while on Avastin, affecting about 15% of surgical patients on the drug compared to 4% without it. Severe high blood pressure develops in 5% to 18% of patients across clinical trials.
These risks are real, but they’re managed through monitoring and careful timing of any surgical procedures. They’re also present regardless of whether Avastin is used as a first-line or later-line treatment.
Avastin Beyond Cancer
Interestingly, Avastin has a completely separate life outside oncology. Eye doctors routinely use it as a first-choice treatment for wet age-related macular degeneration, a condition where abnormal blood vessels grow behind the retina and threaten vision. This use is technically off-label (not FDA-approved for this purpose), but it’s widely practiced and supported by clinical evidence dating back to 2005. The American Academy of Ophthalmology recognizes it as safe and effective for eye disease. In this context, Avastin is the opposite of a last resort: it’s often the first drug injected.
Why the “Last Resort” Perception Exists
Several factors feed this misconception. Avastin is approved for some cancers only in their recurrent or metastatic forms, which are by definition later-stage situations. Patients and families hearing about Avastin for the first time at that point in treatment may reasonably assume it’s being tried because everything else failed. The drug’s serious side effect profile can also make it sound like something reserved for desperate circumstances.
The reality is more straightforward. Avastin is a targeted therapy that occupies different positions in treatment plans depending on the cancer type. For some cancers it’s a starting player, for others it enters the game later. But in none of its approved uses is it classified as a treatment of last resort. It’s a well-established part of standard cancer care across multiple tumor types, backed by over 20 years of clinical use since its initial approval.